Table 2.

JAKi as a second-line option that is most associated with CDAI remission at 24 weeks

JAKi as second-line b/tsDMARDs (n = 127)
	Univariable analysis		Multivariable analysis
	Odds ratio (95% CI)	p value	Odds ratio (95% CI)	p value
TOF	Ref	–
BAR (TOF reference)	2.11 (0.78–5.71)	0.142
UPA (TOF reference)	4.16 (1.43–12.14)	0.007	5.71 (1.62–20.14)	0.007

In the multivariate analysis of factors strongly associated with the achievement of CDAI remission at 24 weeks in RA patients treated with JAKi as second-line b/tsDMARDs, age, sex, disease duration, CDAI, HAQ-DI, and use of MTX at baseline were considered covariates.

b/tsDMARDs biologic/targeted synthetic disease-modifying antirheumatic drugs, JAKi Janus kinase inhibitor, TOF tofacitinib, BAR baricitinib, UPA upadacitinib